2023
Early Detection of Cancers in the Era of Precision Oncology
Tan W, Sharma A, Das P, Ahuja N. Early Detection of Cancers in the Era of Precision Oncology. Current Opinion In Oncology 2023, 35: 115-124. PMID: 36721896, DOI: 10.1097/cco.0000000000000931.Peer-Reviewed Original ResearchUtility of promoter hypermethylation in malignant risk stratification of intraductal papillary mucinous neoplasms
Chhoda A, Sharma A, Sailo B, Tang H, Ruzgar N, Tan W, Ying L, Khatri R, Narayanan A, Mane S, De Kumar B, Wood L, Iacobuzio-Donahue C, Wolfgang C, Kunstman J, Salem R, Farrell J, Ahuja N. Utility of promoter hypermethylation in malignant risk stratification of intraductal papillary mucinous neoplasms. Clinical Epigenetics 2023, 15: 28. PMID: 36803844, PMCID: PMC9942382, DOI: 10.1186/s13148-023-01429-5.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorDNADNA MethylationHumansNeoplasms, Cystic, Mucinous, and SerousPancreatic Intraductal NeoplasmsPancreatic NeoplasmsRisk AssessmentConceptsPapillary mucinous neoplasmMalignant risk stratificationCACNA1G geneRisk stratificationMucinous neoplasmsBiomarker panelBackgroundIntraductal papillary mucinous neoplasmIntraductal papillary mucinous neoplasmEarly detectionPrevious case-control studyHigh-grade dysplasiaCase-control studyPancreatic cancer precursorsReceiver Operating Characteristic (ROC) curve analysisSignificant diagnostic challengeCross-sectional imagingCharacteristic curve analysisOperating Characteristic curve analysisG geneHigh diagnostic specificityPrior validation studiesSignificant procedural riskIPMN tissuesSurgical resectionAdvanced neoplasia
2022
A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence
Heumann T, Baretti M, Sugar E, Durham J, Linden S, Lopez-Vidal T, Leatherman J, Cope L, Sharma A, Weekes C, O’Dwyer P, Reiss K, Monga D, Ahuja N, Azad N. A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Clinical Epigenetics 2022, 14: 166. PMID: 36463226, PMCID: PMC9719150, DOI: 10.1186/s13148-022-01367-8.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAzacitidineDNA MethylationFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalPancreatic NeoplasmsConceptsResectable pancreatic ductal adenocarcinomaCC-486OBS patientsMetastatic settingAdjuvant therapyTreatment-related grade 3Randomized phase II studyMedian age 66Next-line therapyResultsForty-nine patientsMedian treatment durationPhase II studyEvidence of diseaseHigh-risk featuresPhase II trialProgression-free survivalStandard adjuvant therapyPancreatic ductal adenocarcinomaCancer recursEvaluable patientsMedian OSMedian PFSOral azacitidineR1 resectionSubsequent chemotherapy
2021
Late-Stage Pancreatic Cancer Detected During High-Risk Individual Surveillance: A Systematic Review and Meta-Analysis
Chhoda A, Vodusek Z, Wattamwar K, Mukherjee E, Gunderson C, Grimshaw A, Sharma A, Ahuja N, Kastrinos F, Farrell JJ. Late-Stage Pancreatic Cancer Detected During High-Risk Individual Surveillance: A Systematic Review and Meta-Analysis. Gastroenterology 2021, 162: 786-798. PMID: 34813861, DOI: 10.1053/j.gastro.2021.11.021.Peer-Reviewed Original ResearchConceptsLate-stage PDACPancreatic ductal adenocarcinomaHigh-risk individualsHigh-grade precursorsCumulative incidenceAdvanced neoplasiaLate-stage pancreatic cancerTiming of presentationRandom-effects modelWeb of ScienceClinicoradiologic factorsClinicoradiologic featuresSurveillance imagingCochrane LibraryPancreatic cancerDuctal adenocarcinomaPancreatic morphologySurveillance studyFunnel plotLesion sitePDAC stagesSurveillance adherenceSystematic reviewMeta-AnalysisSignificant association